ATC Group: J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J05AB in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J05 Antivirals for systemic use
3 J05A Direct acting antivirals
4 J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors

Group J05AB contents

Code Title
J05AB01 Aciclovir
J05AB02 Idoxuridine
J05AB03 Vidarabine
J05AB06 Ganciclovir
J05AB09 Famciclovir
J05AB11 Valaciclovir
J05AB12 Cidofovir
J05AB13 Penciclovir
J05AB14 Valganciclovir
J05AB15 Brivudine
J05AB16
J05AB17
J05AB18

Active ingredients in J05AB

Active Ingredient Description
Aciclovir

Acyclovir is an antiviral agent with activity against herpes simplex virus and varicella-zoster virus. Acyclovir inhibits the DNA polymerase of the virus, preventing further proliferation.

Brivudine

Brivudine is a thymidine analogue with antiviral activity, indicated for the early treatment of acute herpes zoster in adult patients. Brivudine is incorporated into the viral DNA and blocks the action of DNA polymerases, thus inhibiting viral replication.

Cidofovir

Cidofovir suppresses HCMV replication by selective inhibition of viral DNA synthesis. Biochemical data support selective inhibition of HSV-1, HSV-2 and HCMV DNA polymerases by cidofovir diphosphate, the active intracellular metabolite of cidofovir.

Famciclovir

Famciclovir is the oral prodrug of penciclovir. Famciclovir is rapidly converted in vivo into penciclovir, which has in vitro activity against herpes simplex viruses (HSV types 1 and 2), varicella zoster virus (VZV), Epstein-Barr virus and cytomegalovirus.

Ganciclovir

Ganciclovir, 9-(1,3-dihydroxy-2-propoxymethyl)guanine or DHPG, is a broadspectrum virustatic agent which inhibits the replication of viruses, including viruses of the herpes group, both in vivo and in vitro: herpes simplex types 1 and 2 (HSV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes zoster (HZV).

Molnupiravir

Molnupiravir is indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. Molnupiravir is a prodrug that is metabolised to the ribonucleoside analogue N-hydroxycytidine (NHC) which distributes into cells where it is phosphorylated to form the pharmacologically active ribonucleoside triphosphate (NHC-TP).

Penciclovir

Penciclovir has demonstrated in vivo and in vitro activity against herpes simplex viruses (types 1 and 2) and varicella zoster virus. Penciclovir triphosphate persists in infected cells for more than 12 hours where it inhibits replication of viral DNA and has a half-life of 9, 10 and 20 hours in cells infected with varicella zoster virus, herpes simplex virus type 1 and herpes simplex virus type 2 respectively.

Valaciclovir

Valaciclovir, an antiviral, is the L-valine ester of aciclovir. Valaciclovir is rapidly and almost completely converted in man to aciclovir and valine. Aciclovir is a specific inhibitor of the herpes viruses with in vitro activity against herpes simplex viruses (HSV) type 1 and type 2, varicella zoster virus (VZV), cytomegalovirus (CMV), Epstein-Barr Virus (EBV), and human herpes virus 6 (HHV-6).

Valganciclovir

Valganciclovir is an L-valyl ester (prodrug) of ganciclovir. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine and inhibits replication of herpes viruses in vitro and in vivo.

Vidarabine

Related product monographs

Title Information Source Document Type  
CYCLOVAX Cream Υπουργείο Υγείας (CY) MPI, EU: SmPC
CYCLOVAX Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
CYMEVENE Powder for concentrate for solution Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
CYTOVENE-IV Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
FAMVIR Film-coated tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
LAGEVRIO Hard capsule Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MEDOVIR Cream Υπουργείο Υγείας (CY) MPI, EU: SmPC
MEDOVIR Powder for solution for infusion Υπουργείο Υγείας (CY) MPI, EU: SmPC
MEDOVIR Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
SITAVIG Delayed-release tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
SYNTOVIR Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
VALACICLOVIR Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
VALGANCICLOVIR Film-coated tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
VALTREX Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
VEKLURY Powder for concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
VISTIDE Concentrate for solution for infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ZELITREX Tablet Health Products Regulatory Authority (ZA) MPI, Generic
ZOVIRAX Cream Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ZOVIRAX Dispersible film-coated tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
Zovirax Eye Ointment Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
Zovirax Intravenous injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC